These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 16880168)
1. Analyzing plasma HIV-1 RNA measurements as multiple recurrent events in clinical trials. Flandre P; Pinçon C; Aboulker JP; Brun-Vézinet F; Pialoux G; Raffi F; Descamps D HIV Clin Trials; 2006; 7(3):116-24. PubMed ID: 16880168 [TBL] [Abstract][Full Text] [Related]
2. Progression to AIDS or death as endpoints in HIV clinical trials. Raffi F; Chêne G; Lassalle R; May T; Billaud E; Fleury H; Dellamonica P; Leport C; HIV Clin Trials; 2001; 2(4):330-5. PubMed ID: 11590536 [TBL] [Abstract][Full Text] [Related]
3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
4. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study. Keiser P; Nassar N; White C; Koen G; Moreno S HIV Clin Trials; 2002; 3(4):296-303. PubMed ID: 12187503 [TBL] [Abstract][Full Text] [Related]
5. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl. Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS AIDS; 2006 May; 20(8):1117-23. PubMed ID: 16691062 [TBL] [Abstract][Full Text] [Related]
6. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment. Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932 [TBL] [Abstract][Full Text] [Related]
7. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. Knobel H; Guelar A; Carmona A; Espona M; González A; López-Colomés JL; Saballs P; Gimeno JL; Díez A AIDS Patient Care STDS; 2001 Apr; 15(4):193-9. PubMed ID: 11359661 [TBL] [Abstract][Full Text] [Related]
8. Should we now adopt the HIV-RNA < 50 copy endpoint for clinical trials of antiretroviral-experienced as well as naive patients? Hill A; Miralles D; Vangeneugden T; Lefebvre E AIDS; 2007 Jul; 21(12):1651-3. PubMed ID: 17630565 [TBL] [Abstract][Full Text] [Related]
9. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice. Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A; J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785 [TBL] [Abstract][Full Text] [Related]
10. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy. Gianotti N; Soria A; Galli L; Castagna A; Cernuschi M; Hasson H; Lazzarin A J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657 [TBL] [Abstract][Full Text] [Related]
11. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086 [TBL] [Abstract][Full Text] [Related]
12. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy. Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A; J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976 [TBL] [Abstract][Full Text] [Related]
13. Antiretroviral therapy for HIV-1 vaccine efficacy trial participants who seroconvert. Kim HN; Tabet SR; Corey L; Celum CL Vaccine; 2006 Jan; 24(4):532-9. PubMed ID: 16242816 [TBL] [Abstract][Full Text] [Related]
14. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients. Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104 [TBL] [Abstract][Full Text] [Related]
15. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217 [TBL] [Abstract][Full Text] [Related]
16. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036 [TBL] [Abstract][Full Text] [Related]
17. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC; AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047 [TBL] [Abstract][Full Text] [Related]
18. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. Sterling TR; Vlahov D; Astemborski J; Hoover DR; Margolick JB; Quinn TC N Engl J Med; 2001 Mar; 344(10):720-5. PubMed ID: 11236775 [TBL] [Abstract][Full Text] [Related]